Literature DB >> 19199978

Pleiotropic effects of fenofibrate.

V Tsimihodimos1, E Liberopoulos, M Elisaf.   

Abstract

Fenofibrate represents the most commonly used fibric acid derivative. The drug exerts its metabolic effects by modulating the expression of several genes involved in lipoprotein metabolism. In addition, numerous studies suggest that fenofibrate may also affect the progression of the atherosclerotic process by several lipid-independent mechanisms. This review considers the clinical pharmacology of fenofibrate and the current evidence on the pleiotropic effects of this fibric acid derivative.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19199978     DOI： 10.2174/138161209787315675

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN： 1381-6128            Impact factor:   3.116


  7 in total

Review 1.  Fibrate therapy and renal function.

Authors:  Domenic A Sica
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

Review 2.  Residual microvascular risk in diabetes: unmet needs and future directions.

Authors:  Paola Fioretto; Paul M Dodson; Dan Ziegler; Robert S Rosenson
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

Review 3.  A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

Authors:  Theodosios D Filippatos
Journal:  Cardiovasc Drugs Ther       Date:  2012-06       Impact factor: 3.727

4.  Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection.

Authors:  Neha Sehgal; Kanhaiya Lal Kumawat; Anirban Basu; Vijayalakshmi Ravindranath
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

5.  Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet.

Authors:  Ying Zhang; Xiu-Bin Jia; Yun-Chao Liu; Wen-Qian Yu; Yan-Hong Si; Shou-Dong Guo
Journal:  Front Nutr       Date:  2022-09-12

Review 6.  The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review.

Authors:  Pavan Malur; Arthur Menezes; James J DiNicolantonio; James H O'Keefe; Carl J Lavie
Journal:  Mo Med       Date:  2017 Nov-Dec

7.  Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes.

Authors:  Rebecca Frazier; Rupal Mehta; Xuan Cai; Jungwha Lee; Sara Napoli; Timothy Craven; Jennifer Tuazon; Adam Safdi; Julia Scialla; Katalin Susztak; Tamara Isakova
Journal:  Kidney Int Rep       Date:  2018-09-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.